SCHEMBL4014892

SCHEMBL4014892

Cc1ccc2c(N3CCC[C@@H](N(C)C(=O)O)C3)nc(-c3ccccc3O)nc2c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK2 O96017 6/20 0.59
SMAD3 P84022 1/20 0.51
MAPT P10636 3/20 0.47
KMT2A Q03164 2/20 0.46
MEN1 O00255 1/20 0.46
ALDH1A1 P00352 4/20 0.41
TSHR P16473 2/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
PRKDC P78527 2/20 0.40
KDM4E B2RXH2 3/20 0.39
HPGD P15428 2/20 0.39
HSD17B10 Q99714 2/20 0.39
TDP1 Q9NUW8 2/20 0.39
NPSR1 Q6W5P4 1/20 0.39
USP2 O75604 1/20 0.39
LMNA P02545 1/20 0.39
MAPK1 P28482 1/20 0.39
OPRM1 P35372 1/20 0.39
OPRD1 P41143 1/20 0.39
OPRK1 P41145 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1621751 1.00 CHEK2 (0.59) CHEK2SMAD3MAPTKMT2AMEN1
SCHEMBL4014972 1.00 CHEK2 (0.59) CHEK2SMAD3MAPTKMT2AMEN1
Hydrochloric Acid SCHEMBL4019542 0.99 CHEK2 (0.58) CHEK2SMAD3MAPTKMT2AMEN1
Hydrochloric Acid SCHEMBL4016177 0.99 CHEK2 (0.58) CHEK2SMAD3MAPTKMT2AMEN1
SCHEMBL4014738 0.95 CHEK2 (0.67) CHEK2SMAD3MAPTKMT2AMEN1
SCHEMBL4011372 0.95 CHEK2 (0.67) CHEK2SMAD3MAPTKMT2AMEN1
SCHEMBL5512766 0.95 CHEK2 (0.67) CHEK2SMAD3MAPTKMT2AMEN1
Hydrochloric Acid SCHEMBL4020888 0.94 CHEK2 (0.66) CHEK2SMAD3MAPTKMT2AMEN1
SCHEMBL1624012 0.89 CHEK2 (0.54) CHEK2SMAD3MAPTKMT2AMEN1
SCHEMBL1623240 0.88 CHEK2 (0.54) CHEK2SMAD3MAPTKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090312342-A1 Quinazolines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED 2009-12-17 US disclosed
EP-1784393-B1 QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS VERTEX PHARMA (US) 2009-07-01 EP disclosed
EP-1784393-A1 QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS Vertex Pharmaceuticals Incorporated (US) 2007-05-16 EP disclosed
WO-2006028904-A9 QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS VERTEX PHARMA (US) 2006-06-22 WO disclosed
WO-2006028904-A1 QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2006-03-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312342-A1 Quinazolines useful as modulators of ion channels KCNQ1, KCNQ2, KCNN3 CHEK2 2935/4885SMAD3 4194/4885MAPT 2508/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.